EC Number   |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
|---|
   3.4.21.92 | Infections |
22359499 |
Mycobacterium tuberculosis ClpP1 and ClpP2 Function Together in Protein Degradation and Are Required for Viability in vitro and During Infection. |
ongoing research
therapeutic application
unassigned |
4
1
0 |
| 3.4.21.92 | Infections |
23584755 |
The ClpP peptidase of Wolbachia endobacteria is a novel target for drug development against filarial infections. |
causal interaction
therapeutic application
unassigned |
3
4
0 |
| 3.4.21.92 | Infections |
23995637 |
Regulation of host hemoglobin binding by the Staphylococcus aureus Clp proteolytic system. |
causal interaction
ongoing research
unassigned |
1
3
0 |
| 3.4.21.92 | Infections |
27831584 |
The development of small-molecule modulators for ClpP protease activity. |
causal interaction
unassigned |
4
0 |
| 3.4.21.92 | Infections |
27849175 |
Two isoforms of Clp peptidase in Pseudomonas aeruginosa control distinct aspects of cellular physiology. |
causal interaction
unassigned |
1
0 |
| 3.4.21.92 | Infections |
28271875 |
In Vivo-Selected Pyrazinoic Acid-Resistant Mycobacterium tuberculosis Strains Harbor Missense Mutations in the Aspartate Decarboxylase PanD and the Unfoldase ClpC1. |
diagnostic usage
ongoing research
therapeutic application
unassigned |
1
1
1
0 |
| 3.4.21.92 | Infections |
30543804 |
Development of high throughput screening methods for inhibitors of ClpC1P1P2 from Mycobacteria tuberculosis. |
causal interaction
unassigned |
3
0 |
| 3.4.21.92 | Infections |
30602512 |
Rufomycin Targets ClpC1 Proteolysis in Mycobacterium tuberculosis and M. abscessus. |
therapeutic application
unassigned |
3
0 |
| 3.4.21.92 | Infections |
31409659 |
Dual RNA-seq in Streptococcus pneumoniae Infection Reveals Compartmentalized Neutrophil Responses in Lung and Pleural Space. |
unassigned |
0 |
| 3.4.21.92 | Infections |
32031798 |
Discovery of Novel Peptidomimetic Boronate ClpP Inhibitors with Noncanonical Enzyme Mechanism as Potent Virulence Blockers in Vitro and in Vivo. |
causal interaction
therapeutic application
unassigned |
3
4
0 |
